Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Hyunsoon | - |
dc.contributor.author | Lee, Sanghee | - |
dc.contributor.author | Sim, Sung Hoon | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Kwak, Mi Hyang | - |
dc.contributor.author | Kim, Hak Jin | - |
dc.date.accessioned | 2021-12-09T16:41:51Z | - |
dc.date.available | 2021-12-09T16:41:51Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/130607 | - |
dc.description.abstract | Purpose Cardiotoxicities are adverse effects often reported in chemotherapy-treated breast cancer patients. This study evaluated the potential risk factors and cumulative incidence of doxorubicin-induced cardiotoxicity in Korean breast cancer patients. Methods We retrospectively analyzed the data of 613 breast cancer patients who underwent a multigated acquisition (MUGA) scan or echocardiography prior to chemotherapy and at least one post-chemotherapy follow-up MUGA scan/echocardiography between 2007 and 2016 at National Cancer Center, Korea. The Cox proportional hazards models were used to evaluate cardiotoxicity risks. Competing risks analyses were performed to estimate cumulative incidence of cardiotoxicity. Results Risk factors associated with cardiotoxicity within 2 years of doxorubicin administration included age [adjusted hazard ratio (aHR) = 1.02, 95% confidence interval (CI) 1.00-1.04;p = 0.05], metastasis (aHR = 2.66; 95% CI 1.36-5.20;p < 0.01), and concomitant trastuzumab (aHR = 4.08; 95% CI 2.31-7.21;p < 0.01). The cumulative incidence of patients with cardiotoxicity was 6.1% at 2 years (without substantial change from about 9 months)and 20.2% at 2 years (without substantial change from about 15 months) after initiation of doxorubicin-containing therapy without and with trastuzumab, respectively. Conclusions Susceptibility to chemotherapy-induced cardiotoxicity within 2 years of doxorubicin initiation in breast cancer patients was elevated with old age, metastasis, and concomitant trastuzumab. Regular imaging monitoring at least up to 9 months after doxorubicin initiation in patients treated without concomitant trastuzumab, and 15 months in patients treated with concomitant trastuzumab, is needed for early detection of chemotherapy-induced cardiotoxicity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | CONGESTIVE-HEART-FAILURE | - |
dc.subject | ANTHRACYCLINE CARDIOTOXICITY | - |
dc.subject | CARDIAC TOXICITY | - |
dc.subject | AMERICAN SOCIETY | - |
dc.subject | TARGETED AGENTS | - |
dc.subject | DOXORUBICIN | - |
dc.subject | THERAPY | - |
dc.subject | TRASTUZUMAB | - |
dc.subject | DYSFUNCTION | - |
dc.subject | ECHOCARDIOGRAPHY | - |
dc.title | Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, In Hae | - |
dc.identifier.doi | 10.1007/s10549-020-05703-5 | - |
dc.identifier.scopusid | 2-s2.0-85085570198 | - |
dc.identifier.wosid | 000540533000009 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, v.182, no.2, pp.333 - 343 | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 182 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 333 | - |
dc.citation.endPage | 343 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CONGESTIVE-HEART-FAILURE | - |
dc.subject.keywordPlus | ANTHRACYCLINE CARDIOTOXICITY | - |
dc.subject.keywordPlus | CARDIAC TOXICITY | - |
dc.subject.keywordPlus | AMERICAN SOCIETY | - |
dc.subject.keywordPlus | TARGETED AGENTS | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | DYSFUNCTION | - |
dc.subject.keywordPlus | ECHOCARDIOGRAPHY | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Cardiotoxicity | - |
dc.subject.keywordAuthor | Doxorubicin | - |
dc.subject.keywordAuthor | Heart failure | - |
dc.subject.keywordAuthor | Trastuzumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.